ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1470

Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis

Geoffrey Thiele1, Michael J. Duryee2, Daniel Anderson3, Lynell W. Klassen4, Stephen Mohring5, Kathleen Young6, Dathe Benissan-Messan7, Harlan Sayles3, Jeremy Sokolove8, William H. Robinson9, James O' Dell3, Anthony Nicholas10 and Ted R. Mikuls3, 1Int Med/Sec of Rheum/Immun, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 6Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, 7University of Nebraska Medical Center, Omaha, NE, 8VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 9VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 10Neurology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), osteoarthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Products of oxidative stress, MAA adducts are highly immunogenic and have been associated with tolerance loss.  To examine their potential role in disease-related inflammation, we investigated the presence of MAA adducts and circulating anti-MAA antibody in RA and their relationship with citrullinated proteins and anti-citrullinated protein antibody (ACPA).

Methods:   Synovial tissues from RA and OA patients were examined for the presence of MAA-modified and citrullinated proteins.  Anti-MAA antibody isotypes were measured in RA cases (n = 1720) and healthy controls (n = 80) by ELISA.  Antigen-specific ACPA was measured in RA cases using a multiplex antigen array.  Anti-MAA antibody isotype (IgG, IgM, and IgA) concentrations were compared in a subset of cases (n = 80) and controls (n = 80), matched based on age, gender, race, and smoking status.  Associations of anti-MAA antibody isotypes with disease characteristics, including ACPA, were examined in all RA cases.

Results:  MAA-adducted and citrullinated proteins were detected and shown to co-localize in RA synovial tissues (Fig. 1).  In contrast, MAA adducts were present in negligible quantity while citrullinated proteins were absent in OA synovial tissue.  All anti-MAA antibody isotypes were markedly increased in RA cases vs. controls (p < 0.001).  Among RA cases, anti-MAA antibody isotypes were associated with anti-CCP antibody and RF positivity (p < 0.001) in addition to select measures of disease activity.  Higher anti-MAA antibody concentrations were associated with a higher number of antigen-specific ACPA analytes positive in high titer (p < 0.001) and a higher ACPA score (p < 0.001), defined as the sum of normalized fluorescent values divided by the number of analytes examined (Fig. 2).  Associations of anti-MAA antibody isotypes with ACPA score and the number of analytes positive were independent of other covariates.

Conclusion:   This is the first study to show that MAA adduct formation is increased in RA and appears to result in robust antibody responses that are strongly associated with ACPA.  These results support speculation that MAA adduct formation may be a co-factor that drives tolerance loss resulting in the autoimmune responses characteristic of RA.

Fig. 1:  Immunohistochemical staining of RA synovial tissue demonstrated the presence of: a) citrullinated proteins, b) MAA, and c) co-localization of citrullinated proteins and MAA adducts

Fig. 2: Number of ACPA analytes positive (left) and total ACPA score (right) based on the quintile of circulating IgG anti-MAA antibody; similar results observed for IgA and IgM anti-MAA isotypes (data not shown).


Disclosure:

G. Thiele,
None;

M. J. Duryee,
None;

D. Anderson,
None;

L. W. Klassen,
None;

S. Mohring,
None;

K. Young,
None;

D. Benissan-Messan,
None;

H. Sayles,
None;

J. Sokolove,
None;

W. H. Robinson,

Atreca, Inc.,

5;

J. O’ Dell,
None;

A. Nicholas,
None;

T. R. Mikuls,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/malondialdehyde-acetaldehyde-adducts-maa-and-anti-malondialdehyde-acetaldehyde-antibody-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology